Liraglutide (LR), a glucagon-like peptide-1 (GLP-1) analog with 97% sequence identification with native human GLP-1 is widely known for treating diabetes by slowing gastric emptying, reducing food intake, potentiating glucose-dependent insulin secretion, and stimulating pancreatic beta-cell growth [5]. This evidence concerns the gene GCG and diabetes mellitus.